effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
about
Plasma membrane transporters in modern liver pharmacologyOATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesPediatric Statin Administration: Navigating a Frontier with Limited DataPharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideA systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.BDDCS applied to over 900 drugs.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Impact of OATP transporters on pharmacokinetics.Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects.CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytesComplex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropionPharmacokinetic interaction of garlic and atorvastatin in dyslipidemic ratsElucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersAcute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction.HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsDrug-drug interaction studies: regulatory guidance and an industry perspectiveTransporter-mediated uptake into cellular compartments.Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.Role of OATP transporters in the disposition of drugs.Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions.Effects of drug transporters on volume of distribution.ESRD impairs nonrenal clearance of fexofenadine but not midazolam.The drug transporter-metabolism alliance: uncovering and defining the interplay.The role of transporters in the pharmacokinetics of orally administered drugs.Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives.Clearance (née Rowland) concepts: a downdate and an update.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.
P2860
Q26829263-68F5D047-3F29-4AC4-A267-D2AC8D3A8BB0Q27001267-C849B4A1-A307-423C-9354-CCB44E8CBDB6Q28068014-4A074E08-4CFA-4EFD-8468-75B1449E2BACQ33585344-6B090E91-B4F0-4ADC-A01B-F362FBC0BA98Q33714593-0FFFF97E-7624-4E98-AA1A-6611F49EB4FBQ33891564-53E1C3EC-E184-41DA-9143-1CB426497EFEQ33891588-15724B0F-C321-4603-8839-BC75B5D4FC8EQ34071827-DA410232-04A6-41D4-84F8-5447A3AAAFD3Q34143327-B1664CA1-B98F-487F-B07D-DE7481AD9BE2Q34150929-1CD111C7-9096-42DD-859A-99DF6BD27252Q34206152-A5B9EAE7-833E-477D-8CB9-3F2C5F7BE3C0Q34571070-1032668B-8560-4E63-ACAA-54600ADD11F7Q34612244-A88AA08A-3686-4133-9C5B-2B59BA25CFEDQ34969837-FEE0D213-EB6C-4195-A895-33C221DBCCDDQ35025924-68732C35-5A1E-46AB-B420-CB3DEBC140FFQ35113316-CED5C56A-4703-415C-BACC-1F7DE72A0138Q35120613-0E605366-4D22-4BE3-B83C-FAD3746BB6B4Q35211432-F2B5D92D-4CBD-4BFC-AEF4-FA7DD134420BQ35579531-FD1075FE-F93D-415E-A0C3-22C9A4253B85Q35776626-33C49632-4617-46F2-AED2-E524E19FECB9Q35890427-237B07E0-5716-4912-ABCC-D44EB4F22B02Q36639493-E1612F0A-8C90-462B-B45B-F0A84AF587F8Q36689589-AC2AB4A9-62E0-4916-843E-E3C2DD20733BQ36872923-7612BDB8-8263-40F4-8058-B2B53FFD3261Q36877910-0D91A9D0-1427-4F8E-A3E6-7329EAA67B94Q36951933-0F8AC58F-E381-432C-ABC1-1EBD0544210CQ36985076-97A36060-A914-4FD5-9E46-4013EE2E7419Q37058658-E45A2165-2C60-43AC-8A6B-0AF55F10AF91Q37074085-6A29C2FA-FC24-459C-BAA7-71F50F7163ABQ37130938-85AD9249-0E9D-42B6-8C85-35584C5271F8Q37214523-114EEAC0-0607-459E-9A21-D1950B04A81EQ37367679-33B63080-0D85-4259-8211-FE70F67FFF89Q37485904-A692D2F3-50E9-4A70-AD86-C7A126DA2F65Q37537018-02D57449-D4F0-4A3E-8B89-2D2BC31B8964Q37650803-49D2FF1E-474E-4FD0-859D-F6A498180620Q37696476-32DDD514-2B27-4EAD-AFD1-072509AD35C9Q37709367-E48E269B-4B48-42FC-9A79-257A06F48DA2Q37813042-E5B3DC81-35D1-498D-9C56-4A4254CA8222Q37955160-52A922B2-DCBD-4873-AD2F-E6492CBC7CD8Q37960129-CD07778F-E65B-4FA8-BA35-D7B1A6122DF5
P2860
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
effect of OATP1B transporter i ...... astatin in healthy volunteers.
@en
type
label
effect of OATP1B transporter i ...... astatin in healthy volunteers.
@en
prefLabel
effect of OATP1B transporter i ...... astatin in healthy volunteers.
@en
P2093
P2860
P356
P1476
effect of OATP1B transporter i ...... astatin in healthy volunteers.
@en
P2093
P2860
P304
P356
10.1038/SJ.CLPT.6100038
P407
P577
2006-12-27T00:00:00Z